Related Experiment Videos
Mycophenolate mofetil for myasthenia gravis: an open-label pilot study
E Ciafaloni1, J M Massey, B Tucker-Lipscomb
1Division of Neurology, Duke University Medical Center, Durham, NC, USA. ciafa001@mc.duke.edu
Neurology
|January 10, 2001
Summary
Mycophenolate mofetil effectively treated refractory Myasthenia Gravis (MG) in a small study. Patients showed significant improvement in MG symptoms and reduced corticosteroid dependence with minimal side effects.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Myasthenia Gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
- Refractory MG cases often require additional immunosuppressive therapy beyond corticosteroids.
Purpose of the Study:
- To evaluate the efficacy and safety of mycophenolate mofetil in patients with refractory Myasthenia Gravis.
- To assess the potential for corticosteroid dose reduction in MG patients treated with mycophenolate mofetil.
Main Methods:
- An open-label study involving 12 patients with refractory MG.
- Patients received mycophenolate mofetil 1g twice daily for 6 months.
- Efficacy was defined by a 3-point reduction in Quantified MG score, 2-point improvement in manual muscle test, or 50% corticosteroid dose reduction.
Main Results:
- Eight out of 12 patients demonstrated clinical improvement.
- Improvement onset ranged from 2 weeks to 2 months after treatment initiation.
- No major adverse events were reported during the study period.
Conclusions:
- Mycophenolate mofetil appears to be an effective and safe treatment option for refractory Myasthenia Gravis.
- This immunosuppressant may allow for significant corticosteroid dose reduction in MG patients.